Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03497442
Recruitment Status : Completed
First Posted : April 13, 2018
Last Update Posted : April 1, 2019
Sponsor:
Information provided by (Responsible Party):
Wesley Yu, University of California, San Francisco

Brief Summary:

Asian Flushing Syndrome (AFS) is a genetic disease affecting approximately 70% of patients of East Asian descent characterized by severe flushing with minimal ethanol consumption. This reaction is cosmetically unattractive and socially limiting. Many Asian patients avoid drinking alcohol on dates, at weddings, and during business events because of this reaction and the perception of being drunk or alcoholic.

Ethanol is normally metabolized to acetic acid by two enzymes. The first enzyme, alcohol dehydrogenase (ADH) converts ethanol to acetaldehyde. The second enzyme, aldehyde dehydrogenase 2 (ALDH2) converts the toxic acetaldehyde to harmless acetic acid. When ADH function is increased or ALDH2 function is decreased, the toxic intermediate acetaldehyde accumulates resulting in cutaneous flushing. Over 70% of East Asians have genetic polymorphisms in either ADH or ALDH2 leading to intense flushing with ethanol consumption.

There are no effective topical treatments for the Asian Flushing Syndrome. Oral antihistamines have been used with some success in treating symptoms of Asian Flushing Syndrome; however these can have sedating effects and may be dangerous in combination with alcohol.

Brimonidine is a selective α2-adrenoceptor agonist that acts through vasoconstriction and is commercially available in a topical gel. This topical treatment is FDA approved for the indication of facial flushing and has a long history of safety in human subjects.


Condition or disease Intervention/treatment Phase
Flushing Alcohol-Related Disorders Aldehyde Dehydrogenase Deficiency Drug: Brimonidine Tartrate Drug: Placebo Vehicle Gel Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: This is a split face study. All participants will follow an identical protocol with active medication applied to half of their face and placebo applied to the other half. Treatment and placebo side will be randomized.
Primary Purpose: Treatment
Official Title: Treatment of Asian Flushing Syndrome With Topical Alpha Agonists
Actual Study Start Date : July 12, 2018
Actual Primary Completion Date : March 25, 2019
Actual Study Completion Date : March 25, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment Arm
This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of brimonidine 0.33% gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
Drug: Brimonidine Tartrate
Topical brimonidine tartrate will be applied to one half of each participant's face. A randomization process will be used to determine which side of the face each participant will apply treatment to. The untreated side of the face will receive a placebo vehicle. Patient and clinician will be blinded to treatment side.
Other Name: Mirvaso

Placebo Comparator: Placebo Arm
This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of vehicle gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
Drug: Placebo Vehicle Gel
Vehicle Gel




Primary Outcome Measures :
  1. Clinician Erythema Score [ Time Frame: Evaluated 30 minutes after alcohol consumption ]
    Clinician Erythema Assessment (CEA) Scale Grade 0: Clear skin with no signs of erythema Grade 1: Almost clear of erythema, slight redness Grade 2: Mild erythema, definite redness Grade 3: Moderate erythema, marked redness Grade 4: Severe erythema, fiery redness.

  2. Patient Erythema Self Assessment [ Time Frame: Evaluated 30 minutes after alcohol consumption ]

    Subject self-assessment 0: No signs of unwanted redness

    1. Almost clear of unwanted redness
    2. Mild redness
    3. Moderate redness
    4. Severe redness


Secondary Outcome Measures :
  1. Delayed Clinician Erythema Score [ Time Frame: Evaluated 60 and 90 minutes after alcohol consumption ]
    Clinician Erythema Assessment (CEA) Scale

  2. Delayed Patient Erythema Self Assessment [ Time Frame: Evaluated 60 and 90 minutes after alcohol consumption ]
    Subject self-assessment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female, 21 years of age or older
  • Self-reported East Asian descent defined as being at least partially ethnically Han Chinese, Japanese, or Korean.
  • No persistent facial erythema at baseline as reported by the patient and observed by investigators at first visit
  • Moderate to severe facial erythema (grade of 2 or more on the Clinician Erythema Assessment scale) induced by one standard drink of alcohol as defined by the National Institute on Alcohol Abuse and Alcoholism (12 ounces of beer, 5% alcohol; 5 ounces of wine, 12% alcohol; or 1.5 ounces of distilled spirits, 40% alcohol). Patients must provide a photo of themselves in sufficient lighting after having one standard drink to be confirmed by the investigators at the screening visit.
  • Written informed consent for any and all study procedures
  • Written authorization for use and release of health and research study information
  • Written authorization for use of photos in publications and presentations
  • Ability to follow study instructions and complete study assessment tools without assistance.
  • Ability to communicate with the study team without the need for translators.
  • Female patients of childbearing potential must have a negative urine pregnancy test result at the screening visit.

Exclusion Criteria:

  • Age < 21
  • Known hypersensitivity or allergies to any component of the study treatment
  • Pregnancy or active breastfeeding
  • History of rosacea
  • Exam findings consistent with rosacea
  • Current use of medications for rosacea
  • Current use of oral H1 or H2 antagonists, or use in the last 2 weeks
  • Active acne vulgaris
  • Current use of topical medications for acne vulgaris
  • Any uncontrolled systemic disease or abnormal vital signs at study visit
  • Current use of medications known to cause cutaneous flushing such as rifampin, nicotinic acid, calcium channel blockers (or other antihypertensives), nitroglycerin, prostaglandins, bromocriptine, tamoxifen, thyroid hormone replacement, cyproterone acetate (or other medications to induce fertility), sildenafil citrate, and monoamine oxidase inhibitors
  • Current use of medications known to be contraindicated with alcohol use such as disulfiram, rifampin, isoniazid, isotretinoin, anxiolytics, non-steroidal anti-inflammatory medications, acetaminophen, warfarin, antidepressants, St. John's Wort, cyclobenzaprine and other muscle relaxants, metronidazole, trimethoprim-sulfamethoxazole.
  • History of any of the following conditions: Raynaud's syndrome, orthostatic hypotension, cerebral or coronary insufficiency, congenital or acquired heart disease, thromboangiitis obliterans, alcohol or substance abuse, liver fibrosis or cirrhosis, hepatitis, renal insufficiency, severe gastrointestinal bleeding, seizures, or psychiatric disease.
  • Protected or vulnerable patient groups such as inmates, children and minors, pregnant women, and individuals with cognitive impairment or those who are legally blind, illiterate, or cannot talk or write.
  • Use of any products containing oxymetazoline or brimonidine within 2 weeks of initial study visit.
  • Use of topical glucocorticosteroids applied to the face within 2 weeks of initial study visit
  • Any prior treatment with lasers, intense pulsed light, photodynamic therapy, or other energy based therapy to the face.
  • Facial hair, tattoos, facial characteristics, or cutaneous disease (such as actinic damage, melasma, postinflammatory hyper- or hypopigmentation, excessive telangiectasias, nevi, or other pigmentation) which may interfere with assessments of erythema in the opinion of the investigators.
  • Current enrollment in an investigational drug or device study or participation in such within 30 days of entry into this study.
  • Any condition or situation that, in the investigator's opinion, may put the patient at significant risk, or may significantly interfere with the patient's participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03497442


Locations
Layout table for location information
United States, California
UC, San Francisco
San Francisco, California, United States, 94115
Sponsors and Collaborators
University of California, San Francisco

Publications:
Layout table for additonal information
Responsible Party: Wesley Yu, Principal Investigator, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT03497442     History of Changes
Other Study ID Numbers: 17-23964
First Posted: April 13, 2018    Key Record Dates
Last Update Posted: April 1, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Flushing
Alcohol-Related Disorders
Skin Manifestations
Signs and Symptoms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Brimonidine Tartrate
Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs